{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/SPRY/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-10-19T17:54:51.679Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":6778,"canonical_name":"ARS Pharmaceuticals, Inc.","cik":"0001671858","uei":null,"lei":null,"duns":null,"ticker":"SPRY"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":35},"count":35,"timeline":[{"ts":"2026-10-05","kind":"sec.filing","form_type":"4","title":"4 — ARS Pharmaceuticals, Inc. — 2026-10-05","url_slug":"/sec/cik-0001671858/4/0002135296-26-000009","accession_number":"0002135296-26-000009","importance":30},{"ts":"2026-10-01","kind":"sec.filing","form_type":"144","title":"144 — ARS Pharmaceuticals, Inc. — 2026-10-01","url_slug":"/sec/cik-0001671858/144/0001950047-26-009969","accession_number":"0001950047-26-009969","importance":30},{"ts":"2026-09-30","kind":"sec.filing","form_type":"144","title":"144 — ARS Pharmaceuticals, Inc. — 2026-09-30","url_slug":"/sec/cik-0001671858/144/0001950047-26-009892","accession_number":"0001950047-26-009892","importance":30},{"ts":"2026-09-11","kind":"sec.form144","reporter":"RICHARD LOWENTHAL","title":"Officer, Director, 10% Stockholder","shares":35000,"usd_value":176995,"security_title":"Common","approx_sale_date":"2026-09-11","accession_number":"0001950047-26-009340","importance":40.035399},{"ts":"2026-09-11","kind":"sec.form144","reporter":"ERIC KARAS","title":"Officer","shares":14064,"usd_value":69762,"security_title":"Common","approx_sale_date":"2026-09-11","accession_number":"0001950047-26-009329","importance":40.013952332},{"ts":"2026-09-02","kind":"sec.filing","form_type":"4","title":"4 — ARS Pharmaceuticals, Inc. — 2026-09-02","url_slug":"/sec/cik-0001671858/4/0002149973-26-000004","accession_number":"0002149973-26-000004","importance":30},{"ts":"2026-09-01","kind":"sec.filing","form_type":"144","title":"144 — ARS Pharmaceuticals, Inc. — 2026-09-01","url_slug":"/sec/cik-0001671858/144/0001950047-26-008961","accession_number":"0001950047-26-008961","importance":30},{"ts":"2026-08-31","kind":"sec.filing","form_type":"144","title":"144 — ARS Pharmaceuticals, Inc. — 2026-08-31","url_slug":"/sec/cik-0001671858/144/0001950047-26-008852","accession_number":"0001950047-26-008852","importance":30},{"ts":"2026-08-20","kind":"sec.filing","form_type":"144","title":"144 — ARS Pharmaceuticals, Inc. — 2026-08-20","url_slug":"/sec/cik-0001671858/144/0001950047-26-008488","accession_number":"0001950047-26-008488","importance":30},{"ts":"2026-08-19","kind":"sec.filing","form_type":"144","title":"144 — ARS Pharmaceuticals, Inc. — 2026-08-19","url_slug":"/sec/cik-0001671858/144/0001950047-26-008389","accession_number":"0001950047-26-008389","importance":30},{"ts":"2026-08-18","kind":"sec.filing","form_type":"144","title":"144 — ARS Pharmaceuticals, Inc. — 2026-08-18","url_slug":"/sec/cik-0001671858/144/0001950047-26-008362","accession_number":"0001950047-26-008362","importance":30},{"ts":"2026-08-17","kind":"sec.filing","form_type":"3","title":"3 — ARS Pharmaceuticals, Inc. — 2026-08-17","url_slug":"/sec/cik-0001671858/3/0002149973-26-000002","accession_number":"0002149973-26-000002","importance":30},{"ts":"2026-08-13","kind":"sec.filing","form_type":"10-Q","title":"10-Q — ARS Pharmaceuticals, Inc. — 2026-08-13","url_slug":"/sec/cik-0001671858/10-q/0001193125-26-349140","accession_number":"0001193125-26-349140","importance":45},{"ts":"2026-08-13","kind":"sec.filing","form_type":"8-K","title":"8-K — ARS Pharmaceuticals, Inc. — 2026-08-13","url_slug":"/sec/cik-0001671858/8-k/0001193125-26-349127","accession_number":"0001193125-26-349127","importance":35},{"ts":"2026-07-27","kind":"sec.filing","form_type":"SCHEDULE 13G","title":"SCHEDULE 13G — ARS Pharmaceuticals, Inc. — 2026-07-27","url_slug":"/sec/cik-0001671858/schedule-13g/0002012383-26-002251","accession_number":"0002012383-26-002251","importance":55},{"ts":"2026-07-17","kind":"sec.filing","form_type":"8-K","title":"8-K — ARS Pharmaceuticals, Inc. — 2026-07-17","url_slug":"/sec/cik-0001671858/8-k/0001193125-26-307773","accession_number":"0001193125-26-307773","importance":35},{"ts":"2026-07-07","kind":"sec.filing","form_type":"8-K","title":"8-K — ARS Pharmaceuticals, Inc. — 2026-07-07","url_slug":"/sec/cik-0001671858/8-k/0001193125-26-297554","accession_number":"0001193125-26-297554","importance":35},{"ts":"2026-07-02","kind":"sec.filing","form_type":"4","title":"4 — ARS Pharmaceuticals, Inc. — 2026-07-02","url_slug":"/sec/cik-0001671858/4/0002135296-26-000007","accession_number":"0002135296-26-000007","importance":30},{"ts":"2026-06-26","kind":"sec.filing","form_type":"4","title":"4 — Thompson Peter A. — 2026-06-26","url_slug":"/sec/cik-0001357522/4/0001357522-26-000005","accession_number":"0001357522-26-000005","importance":30},{"ts":"2026-06-26","kind":"sec.filing","form_type":"4","title":"4 — ARS Pharmaceuticals, Inc. — 2026-06-26","url_slug":"/sec/cik-0001671858/4/0001193125-26-285521","accession_number":"0001193125-26-285521","importance":30},{"ts":"2026-06-26","kind":"sec.filing","form_type":"4","title":"4 — ARS Pharmaceuticals, Inc. — 2026-06-26","url_slug":"/sec/cik-0001671858/4/0001952533-26-000002","accession_number":"0001952533-26-000002","importance":30},{"ts":"2026-06-25","kind":"sec.filing","form_type":"8-K","title":"8-K — ARS Pharmaceuticals, Inc. — 2026-06-25","url_slug":"/sec/cik-0001671858/8-k/0001193125-26-282994","accession_number":"0001193125-26-282994","importance":35},{"ts":"2026-06-12","kind":"sec.form144","reporter":"ERIC KARAS","title":"Officer","shares":25000,"usd_value":250000,"security_title":"Common","approx_sale_date":"2026-06-12","accession_number":"0001950047-26-006004","importance":40.05},{"ts":"2026-06-12","kind":"sec.form144","reporter":"ALEXANDER FITZPATRICK","title":"Officer","shares":3355,"usd_value":33550,"security_title":"Common","approx_sale_date":"2026-06-12","accession_number":"0001950047-26-005998","importance":40.00671},{"ts":"2026-06-12","kind":"sec.insider.s","reporter":"Karas Eric","title":"Chief Commercial Officer","shares":25000,"price_per_share":10,"usd_value":250000,"security_title":"Common Stock","importance":35.25},{"ts":"2026-06-12","kind":"sec.insider.s","reporter":"Fitzpatrick Alexander A","title":"Chief Legal Officer","shares":3355,"price_per_share":10,"usd_value":33550,"security_title":"Common Stock","importance":35.03355},{"ts":"2026-06-12","kind":"sec.filing","form_type":"144","title":"144 — ARS Pharmaceuticals, Inc. — 2026-06-12","url_slug":"/sec/cik-0001671858/144/0001950047-26-006004","accession_number":"0001950047-26-006004","importance":30},{"ts":"2026-06-12","kind":"sec.filing","form_type":"4","title":"4 — ARS Pharmaceuticals, Inc. — 2026-06-12","url_slug":"/sec/cik-0001671858/4/0001951287-26-000004","accession_number":"0001951287-26-000004","importance":30},{"ts":"2026-06-12","kind":"sec.insider.m","reporter":"Karas Eric","title":"Chief Commercial Officer","shares":25000,"price_per_share":1.5,"usd_value":37500,"security_title":"Common Stock","importance":15.0375},{"ts":"2026-06-01","kind":"sec.filing","form_type":"3","title":"3 — ARS Pharmaceuticals, Inc. — 2026-06-01","url_slug":"/sec/cik-0001671858/3/0002135296-26-000005","accession_number":"0002135296-26-000005","importance":30},{"ts":"2026-05-15","kind":"sec.filing","form_type":"10-Q","title":"10-Q — ARS Pharmaceuticals, Inc. — 2026-05-15","url_slug":"/sec/cik-0001671858/10-q/0001193125-26-225142","accession_number":"0001193125-26-225142","importance":45},{"ts":"2026-05-15","kind":"sec.filing","form_type":"8-K","title":"8-K — ARS Pharmaceuticals, Inc. — 2026-05-15","url_slug":"/sec/cik-0001671858/8-k/0001193125-26-225055","accession_number":"0001193125-26-225055","importance":35},{"ts":"2026-05-15","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — ARS Pharmaceuticals, Inc. — 2026-05-15","url_slug":"/sec/cik-0001671858/schedule-13g-a/0001104659-26-062527","accession_number":"0001104659-26-062527","importance":30},{"ts":"2026-05-13","kind":"sec.filing","form_type":"8-K","title":"8-K — ARS Pharmaceuticals, Inc. — 2026-05-13","url_slug":"/sec/cik-0001671858/8-k/0001193125-26-220671","accession_number":"0001193125-26-220671","importance":35},{"ts":"2026-04-27","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — ARS Pharmaceuticals, Inc. — 2026-04-27","url_slug":"/sec/cik-0001671858/schedule-13g-a/0002012383-26-001716","accession_number":"0002012383-26-001716","importance":30}]}